Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

EUROS aggregates the world's financial press. The full article lives with the newsroom that reported it.